Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 106

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 106
---
Depreciation and amortization444 332 112 34 %1,311 819 492 60 %Other expenses1,142 1,006 136 14 %3,967 3,376 591 18 %Allocations1,855 1,851 4 — %5,901 4,857 1,044 21 %Total$15,981 $17,574 $(1,593)(9)%$49,965 $50,004 $(39)— %

Research and development expense decreased $1.6 million, or 9%, for the three months ended September 30, 2025 compared to the same period in 2024. The decrease was primarily due the deconsolidation of Veracyte SAS and the timing of direct research and product development expense related to our on-going development costs for our IVD and MRD strategies, partially offset by increased headcount expenses.

Research and development expense for the nine months ended September 30, 2025 was unchanged compared to the same period in 2024. A decrease due to the timing of spend related to direct research and product development expense related to our on-going development costs for our U.S. CLIA, IVD and MRD strategies was offset by increases in annual compensation expense and our allocated costs from general and administrative expenses.

Selling and marketing

Comparison of the three and nine months ended September 30, 2025 and 2024 is as follows (in thousands of dollars, except percentages):

 Three Months Ended September 30,Nine Months Ended September 30, 20252024Change%20252024Change%Selling and marketing expense:        Compensation expense$16,977 $15,814 $1,163 7 %$52,214 $50,517 $1,697 3 %Direct marketing expense1,376 1,427 (51)(4)%3,564 4,613 (1,049)(23)%Other expenses3,332 3,271 61 2 %10,880 9,897 983 10 %Allocations2,770 2,100 670 32 %7,567 5,583 1,984 36 %Total$24,455 $22,612 $1,843 8 %$74,225 $